Double motion of upper eyelids in Graves’ orbitopathy: an additional sign for detection of thyroid dysfunction or positive thyroid autoantibodies by Kakizaki, Hirohiko et al.
© 2011 Kakizaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2011:5 327–330
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
327
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S17572
Double motion of upper eyelids in graves’ 
orbitopathy: an additional sign for detection  
of thyroid dysfunction or positive thyroid  
autoantibodies
hirohiko Kakizaki1
Yasuhiro Takahashi1
Masayoshi iwaki1
Akihiro ichinose2
Dinesh selva3
igal Leibovitch4
1Department of Ophthalmology, Aichi 
Medical University, nagakute, Aichi, 
Japan; 2Department of Plastic surgery, 
Kobe University, Chuo, Kobe, hyogo, 
Japan; 3south Australian institute of 
Ophthalmology and Discipline of 
Ophthalmology and Visual sciences, 
University of Adelaide, south 
Australia, Australia; 4Division of 
Oculoplastic and Orbital surgery, 
Department of Ophthalmology, 
Tel-Aviv Medical Center, Tel-Aviv 
University, Tel-Aviv, israel
Correspondence: hirohiko Kakizaki 
Department of Ophthalmology,  
Aichi Medical University, nagakute,  
Aichi 480-1195, Japan 
Tel +81 561 62 3311 
Fax +81 561 63 7255 
email cosme@d1.dion.ne.jp
Purpose: To assess the effectiveness of the upper eyelid double motion sign in Graves’ 
orbitopathy (GO) in detecting thyroid dysfunction or a positive level of thyroid-related 
  autoantibodies.
Methods: GO was defined when more than two GO-related eyelid symptoms, including the 
double motion sign, existed with at least one positive thyroid-related blood test. Blood tests 
were performed in patients with more than two GO-related eyelid symptoms. The double motion 
was defined when the upper eyelid stopped at least once during downward eye movement. Fifty 
patients without GO or other eyelid diseases were used as controls.
Results: There were 353 patients who showed more than two GO-related eyelid symptoms 
including the upper eyelid double motion sign. Of these, 300 patients were diagnosed with GO 
(300/353, 85.0%). The double motion sign was demonstrated in 267 patients (75.6%). A pause 
in double motion was typically seen around the anterosuperior direction of gaze. Double motion 
was not seen in any of the control eyelids. Although only 7.0% were hyperthyroid and 8.6% were 
hypothyroid, thyroid related autoantibodies were shown in 73.9% of patients. When the double 
motion sign was removed from the diagnostic criteria of GO, 263 patients had more than two 
thyroid-related eyelid symptoms, including 223 patients diagnosed as GO (25.7% reduction), 
although the rate of a correct diagnosis was almost the same (84.8%).
Conclusions: The double motion sign of the upper eyelids is frequently demonstrated in GO 
patients. This previously unreported sign can help in detecting thyroid dysfunction states with 
positive levels of autoantibodies.
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Introduction
Graves’ orbitopathy (GO) may precede, appear simultaneously to, or follow the actual 
symptoms of Graves’ disease.1 In 10% of patients in whom orbitopathy appears first 
(“euthyroid Graves”), recognition of subtle signs and symptoms related to GO can 
sometimes be a useful tool in early diagnosis and effective treatment of Graves’ 
disease.1,2
Almost all patients with thyroid dysfunctions are thought to have GO, including 
a mild symptom,1,3 although 25%–50% of patients with Graves’ disease3 and 3% 
of those with Hashimoto thyroiditis4 have symptoms of GO. While Graves’ disease 
is easily diagnosed based on the typical signs and symptoms,1 the symptoms in 
hypothyroidism are much more subtle.4,5 It is not uncommon for the symptoms in Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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hypothyroidism to initially be thought to be age related, or 
due to depression or dementia,6 which results in a delay 
in the correct   diagnosis.4 Since hypothyroidism occurs in 
10%–15% of adults older than 60 years of age,7,8 recogniz-
ing GO-related eyelid   symptoms may help in an earlier 
detection.
GO-related symptoms may indicate the existence of 
thyroid dysfunction or thyroid-related self-antibodies. The 
typical eyelid symptoms in GO, such as Dalrymple’s sign, 
Graefe’s sign, Griffice’s sign, and Enroth’s sign, are   usually 
easily detected,1 but can still be quite obscure in some 
cases.
In our practice, we noticed a unique eyelid sign in patients 
with GO, which we named “the upper eyelid double motion 
sign”. This sign is noted during downward eye movement 
when Graefe’s sign is analyzed.9 A pause in the double motion 
is seen around the anterosuperior direction of gaze. To the 
best of our knowledge, this double motion sign has not been 
reported previously.
In this study, we examined the effectiveness of the 
double motion sign as an additional GO-related eyelid sign 
for detection of thyroid dysfunction or a positive level of 
thyroid-related autoantibodies.
Materials and methods
This study was performed from September 2001 to December 
2002 at a general eye clinic, not at a particular oculoplastic 
or a GO clinic.
In our study, we defined GO when more than two of 
the GO-related eyelid symptoms (Dalrymple’s sign [upper 
eyelid retraction], Graefe’s sign, Griffice’s sign [lower 
eyelid lag], and Enroth’s sign [eyelid swelling or   fullness]) 
existed, including the double motion of the upper eyelids 
(defined as at least one pause during downward move-
ment of the upper eyelid),1 in addition to at least one 
positive result from the following thyroid-related blood 
tests: thyroid-stimulating hormone (TSH) (normal range: 
0.35–4.94 µU/mL), free T4 (normal range: 0.70–1.48 ng/dL), 
free T3 (normal range: 1.71–3.71 pg/mL), thyroglobulin (TG) 
(normal range: 30 ng/mL), anti-TG antibody   (anti-TGAb) 
(normal range: less than 0.3 IU/mL),   thyroid receptor   antibody 
(TRAb) (normal range: −15%–15%), thyroid-stimulating 
antibody (TSAb) (normal range: less than 180%), and anti-
thyroid-peroxydase antibody (anti-TPOAb) (normal range: 
less than 0.1 IU/mL). These thyroid-related blood tests were 
performed in patients with more than two   GO-related eyelid 
symptoms, including the upper eyelid double motion sign.
Fifty volunteers (100 eyelids) without GO-related eyelid 
symptoms or other eyelid diseases were used as a control 
group. No thyroid-related blood tests were taken from these 
volunteers as they had no signs of GO or symptoms of   thyroid 
dysfunction.
Consent to participate in the study was obtained from 
all patients and volunteers in the control group, after being 
informed of the purpose and outline of this study.
Results
A total of 353 patients (702 eyelids) had more than two 
GO-related eyelid symptoms including the upper eyelid 
double motion sign. Enroth’s sign was demonstrated in 335 
out of 353 patients (669 eyelids: 94.9%), Griffice’s sign 
in 210 patients (408 eyelids: 59.4%), Dalrymple’s sign in 
102 patients (199 eyelids: 28.9%), and Graefe’s sign in 
13 patients (23 eyelids: 3.7%).
A total of 267 out of 353 patients (534 eyelids: 75.6%) 
demonstrated the double motion sign (Figures 1A and 1B). 
Figure 1 Double motion sign of the upper eyelid. A) Upper eyelid partially covers 
the upper part of the cornea on a slight upward gaze. B) The upper eyelid is still in 
the same position, but the eye moves downward, exposing the sclera between the 
upper eyelid and the cornea.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Of these patients, 37 (13.9%) were not diagnosed with GO 
(Table 1). The double motion was seen around the antero-
superior direction of gaze during downward eye   movement. 
Although the Graefe’s sign was shown in 13 patients 
(22 eyelids), multiple irregular pauses were demonstrated on 
downgaze. All eyelids used as control did not demonstrate 
the double motion sign.
A total of 300 patients out of 353 (85.0%: total 596 eyelids; 
107 males, 213 eyelids; 193 females, 383 eyelids) were 
  diagnosed with GO, from which 253 patients (84.3%) were 
euthyroid, 21 patients (7%) were hyperthyroid, and 26 patients 
(8.6%) were hypothyroid. The other blood tests were as fol-
lows: TSH (28 patients out of 353: 7.93%), TG (105 patients, 
29.7%), anti-TGAb (59 patients, 16.7%), TRAb (42 patients, 
11.9%), TSAb (209 patients, 59.2%), and anti-TPOAb (168 
patients, 47.6%). Emergence of   autoantibodies was 73.7% 
(260 out of 353 patients).
The sensitivity of the double motion of the upper eyelids 
in detecting GO was 76.7% and the specificity was 30.2%.
When the double motion sign is not included in the 
diagnosis of GO, only 263 patients showed more than two 
GO-related eyelid symptoms, and 223 patients were diag-
nosed with GO (25.7% reduction in the number of the GO 
patients), although the rate of a correct diagnosis was almost 
the same (84.8%).
Discussion
The upper eyelid double motion sign was demonstrated 
in around 75% of patients. In addition, many patients 
demonstrated Enroth’s (94.9%) and Griffith (59.4%) signs. 
Therefore, the double motion of upper eyelids sign, as well 
as the Enroth’s and/or Griffith’s signs are useful screening 
tools for ruling out thyroid dysfunction and the existence of 
thyroid-related autoantibodies. A total of 37 patients with 
negative blood tests also showed the double motion sign, and 
this can possibly be explained by the concept of “euthyroid 
Graves’ disease”.1,2
The sensitivity of the double motion of the upper eyelids 
sign in detecting GO was 76.7%, and the specificity was 
30.2%. Hence, when the double motion sign is   positive, 
76.7% of patients (a relatively high percentage), were 
diagnosed with GO. However, since the specificity is not 
as high, even when the double motion sign is negative, GO 
cannot be excluded. Although this may be a drawback, the 
existence of other GO-related symptoms may compensate 
for the low specificity.
In patients with a positive Graefe’s sign, which may rep-
resent a more severe degree of inflammation or fibrosis of the 
levator palpebrae superioris muscle (LPSM) compared with 
the simple upper eyelid double motion sign, there were more 
frequent pauses or multiple motions except for the slightly 
upward site of the primary eye position. Based on this, the 
double motion of the upper eyelids may actually be a mild 
or subtle presentation of Graefe’s sign.
The pause in the double motion, which is located around 
the anterosuperior direction of gaze, may be induced by a 
transient weak traction between the superior rectus muscle 
(SRM) and the LPSM. As communicating fibers connect the 
SRM to the LPSM,10 the upper eyelid moves synchronously 
with the SRM.10 However, when the LPSM changes its direc-
tion from forward to downward,10 the tension of the commu-
nicating fibers may be loosened at the point. Enhanced by the 
limited extension of the LPSM in GO, downward movement 
of the upper eyelids may be in delay to the globe movement 
around the position where the SRM traction is weaker.
Most patients in the present study (84.3%) were euthy-
roid and only a minority (7% and 8.6%) were hyperthyroid 
and hypothyroid, respectively. Most of them were also 
diagnosed with GO without any general symptoms. In the 
general population, it is well documented that most patients 
with GO are hyperthyroid.11–13 A study from the Mayo 
Clinic13 reported that 90% were hyperthyroid, 0.8% were 
hypothyropid, 5.8% were euthyroid, and 3.3% were diag-
nosed with Hashimoto thyroiditis. Since our study analyzed 
patients from a general eye clinic, and not from a particular 
oculoplastic or a GO clinic, this may explain the differences 
in the percentages.
Dalrymple’s sign (upper eyelid retraction) was shown 
in only 28.9% of patients in the present study. In general, 
Dalrymple’s sign is most frequently demonstrated as a 
GO-related eyelid symptom.14 One of the causes of upper 
eyelid retraction is increased sympathetic activity,14 which 
may be due to the effect of a high level of catecholamines in 
hyperthyroidism.11,15 As hyperthyroidism was noted in only 
7% of patients in the current study, it may explain the low 
frequency of upper eyelid retraction.
Table 1 The relationship between the double motion sign of the 
upper eyelids and thyroid eye disease
Graves’ orbitopathy Total
Positive Negative
Double motion Positive 230 37 267
negative 70a 16 86
Total 300 53 353
Note: aThirteen patients demonstrated the graefe’s sign.Clinical Ophthalmology
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When the double motion sign was not included in   diagnostic 
criteria for GO, only 223 patients were diagnosed with GO 
(25.7% reduction in the number of the GO patients). This 
actually means that patients with Graves’ disease may have 
been left without any treatment. Diagnosing Graves’ disease 
is especially important in older patients since the symptoms 
of the disease in this age group are not always clear.
In conclusion, the double motion sign, which may rep-
resent a possible mild form of Graefe’s sign, was frequently 
shown in GO patients but not in the control group. The sign 
is typically seen on a slightly upward site of the primary eye 
position during downward eye movement. The sign can help 
in detecting patients with thyroid dysfunction states and with 
positive levels of autoantibodies.
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